Clinical trialNCT05788289TerminatedPhase 2Interventional

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment4MCLMantle Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Anita Kumar, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering Basking Ridge (all Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (all Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (all Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk- Commack (all Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (all Protocol Activities)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (all Protocol Activities)
Rockville Centre, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lenalidomide →Tafasitamab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Mar 2023
Primary completion: 1 Aug 2024
Completion: 1 Aug 2024
Last update posted: 25 May 2025
Registered enrollment: 4
Registry id: NCT05788289

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.